at CNBC.com (Sep 15, 2014)
InterMune (ITMN -16.4%) tumbles on news that a key clinical trial for its respiratory drug...
InterMune (ITMN -16.4%) tumbles on news that a key clinical trial for its respiratory drug Esbriet has been delayed. Last week, ITMN said it didn't expect enrollment for the Phase 3 clinical trial to be completed until the end of 2012; it had previously forecast enrollment would be completed in Q2. Citing the delay, Jefferies and Leerink Swann cut price targets on the shares.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at CNBC.com (Sep 11, 2014)
at MarketWatch.com (Sep 11, 2014)
at CNBC.com (Aug 28, 2014)
at CNBC.com (Aug 26, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs